Targeted Metabolomics for Plasma Amino Acids and Carnitines in Patients with Metabolic Syndrome Using HPLC-MS/MS
| Autor: | Lihong Liu, Fei-fei Han, Wen Zhang, He Liu, Lingling Xuan, Ya-li Lv, Li-li Gong, Song Yang |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
0301 basic medicine Medicine (General) Article Subject Clinical Biochemistry 030209 endocrinology & metabolism Disease Type 2 diabetes Pharmacology 03 medical and health sciences R5-920 0302 clinical medicine Tandem Mass Spectrometry Carnitine Genetics medicine Humans Metabolomics In patient Amino Acids Molecular Biology Chromatography High Pressure Liquid Metabolic Syndrome chemistry.chemical_classification business.industry Biochemistry (medical) Case-control study General Medicine medicine.disease Amino acid 030104 developmental biology chemistry Case-Control Studies Female Metabolic syndrome business Biomarkers Research Article Targeted metabolomics medicine.drug |
| Zdroj: | Disease Markers Disease Markers, Vol 2020 (2020) |
| ISSN: | 1875-8630 0278-0240 |
| DOI: | 10.1155/2020/8842320 |
| Popis: | Metabolic syndrome (MetS) is a health disorder characterized by metabolic abnormalities that predict an increased risk to develop cardiovascular disease (CVD) and type 2 diabetes. Biomarkers can provide an insight into the novel mechanism for MetS and can be potentially used for personalized response to therapies. We exploited a targeted HPLC-MS/MS method to characterize plasma amino acids and carnitine metabolic profile in MetS patients. A training set (40 cases and 40 controls) and validation set (80 MetS patients and 80 healthy controls) were carried out to find the metabolic profiles. We discovered two carnitine metabolites including hydroxydecanoyl carnitine and methylglutarylcarnitine. Our results indicated that the decreased level of hydroxydecanoyl carnitine and methylglutarylcarnitine may be associated with the risk of MetS. These biomarkers may improve the risk prediction and provide a novel tool for monitoring of the progression of disease and response to treatment in MetS patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text